NCT01426100

CKD-828 Telmisartan Non-Responder Trial

A Randomized, Double-blind, Multi-center, Phase 3 Trial to Evaluate the Efficacy and Safety of a Fixed Dose Combination of Telmisartan and S-Amlodipine(CKD-828) Versus Telmisartan Monotherapy in Hypertensive Patients Inadequately Controlled by Telmisartan Monotherapy

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 183 (actual)
• Sponsor: Chong Kun Dang Pharmaceutical · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	CKD-828 40/2.5mg	Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
DRUG	CKD-828 40/5mg	Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
DRUG	Telmisartan 80mg	Telmisartan 80mg monotherapy

Timeline

• Start date: 2011-08-01
• Primary completion: 2012-05-01
• Completion: 2012-08-01
• First posted: 2011-08-31
• Last updated: 2012-09-13

Locations

18 sites across 1 country: South Korea